---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289210384.md"
description: "Seaport Therapeutics shares are trading higher after the company announced data from the multiple-ascending dose portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo in healthy volunteers."
datetime: "2026-06-09T14:55:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289210384.md)
  - [en](https://longbridge.com/en/news/289210384.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289210384.md)
---

# 

Seaport Therapeutics shares are trading higher after the company announced data from the multiple-ascending dose portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo in healthy volunteers.

### Related Stocks

- [SPTX.US](https://longbridge.com/en/quote/SPTX.US.md)

## Related News & Research

- [Seaport Therapeutics Q2 FY26 net loss widens to $62.6 million; R&D expenses rise to $24.62 million](https://longbridge.com/en/news/294682349.md)
- [Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data From Phase 1 Proof-Of-Concept Trial Of Glyphago™ In Healthy Volunteers](https://longbridge.com/en/news/289044990.md)
- [General Atlantic Discloses Investment at Seaport Therapeutics with 11.5% Stake](https://longbridge.com/en/news/286010382.md)
- [HC Wainwright Has Negative Outlook for SPTX FY2026 Earnings](https://longbridge.com/en/news/295102115.md)
- [Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week High  - Time to Buy?](https://longbridge.com/en/news/295162148.md)